Enanta Pharmaceuticals (ENTA) to Release Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) is expected to issue its Q3 2026 results before the market opens on Monday, August 10th. Analysts expect Enanta Pharmaceuticals to announce earnings of ($0.5095) per share and revenue of $16.7630 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. The business had revenue of $17.16 million during the quarter, compared to analyst estimates of $17.03 million. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%. On average, analysts expect Enanta Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enanta Pharmaceuticals Stock Up 0.6%

ENTA traded up $0.08 during midday trading on Monday, hitting $12.68. 3,465 shares of the company traded hands, compared to its average volume of 194,622. The company’s 50-day moving average is $13.09 and its 200 day moving average is $13.42. The firm has a market capitalization of $368.73 million, a PE ratio of -4.88 and a beta of 0.98. Enanta Pharmaceuticals has a 52 week low of $6.45 and a 52 week high of $17.15.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its position in shares of Enanta Pharmaceuticals by 674.7% in the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock worth $1,971,000 after purchasing an additional 311,010 shares during the period. Millennium Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after acquiring an additional 449,945 shares during the period. Goldman Sachs Group Inc. grew its holdings in Enanta Pharmaceuticals by 5.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after buying an additional 6,549 shares in the last quarter. Invesco Ltd. grew its position in shares of Enanta Pharmaceuticals by 4.3% during the second quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after purchasing an additional 2,607 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Enanta Pharmaceuticals by 0.8% in the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after purchasing an additional 6,522 shares during the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ENTA shares. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $20.29.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.